Title
Scalable Transient CHO Method that in 7-12 days may become Stable Cell Pools & Stable Lines for Quantities needed in Toxicology Studies
Description
Increasing competition in recombinant antibody and protein drug discovery has resulted from the U.S. Patent Office instituting 'First to File'. As a result, the time frame for generating patentable biologic molecules has been extremely compressed. Companies are now forced to utilize methods that can significantly speed transient hits through to st...
Product Used
Related Products
125mL 8 Position Carrier
Use with Optimum Growth® 125mL Flask
pn#1212900
Multiported Optimum Growth® 125mL Flask
PTFE 0.2µm Vent Cap for Increased Aeration | Sterile
pn#931110-DP
Rapid Clear® Cap 3000
High-speed clarification of 3L of cell culture | Sterile
pn#788116
Optimum Growth® 5L Flask
PTFE 0.2µm Vent Cap for Increased Aeration | Sterile
pn#931116
Inversion Transfer Cap for Optimum Growth® 5L Flask
2' of C-Flex® 24 (O.D. 7/16") w/ Plug | Sterile
pn#931598-4
Scalable Transient CHO Method that in 7-12 days may become Stable Cell Pools & Stable Lines for Quantities needed in Toxicology Studies
Joseph Abad2, James Brady2, Weili Wang2, Joe Machamer1, Ana Sirianni1, Sam Ellis1
1Thomson Instrument Company, Oceanside, CA
2Maxcyte, Gaithersburg, MD
Increasing competition in recombinant antibody and protein drug discovery has resulted from the U.S. Patent Office instituting 'First to File'. As a result, the time frame for generating patentable biologic molecules has been extremely compressed. Companies are now forced to utilize methods that can significantly speed transient hits through to stable pools and clones. Thomson Instrument Company and MaxCyte will show new methodology to produce scalable recombinant antibodies and proteins that will lead to faster and higher titers with excellent glycosylation. Our technical advancements in shake flask design, and improvements in transfection significantly shorten timelines and improve product quality allowing for faster filing.